News >

Novel Combo Elicits Clinical Responses in Patients With "Cold" Melanomas

Jessica Hergert
Published: Wednesday, May 13, 2020

Adil Daud, MD, a clinical professor in the Department of Medicine (Hematology/Oncology), at the University of California, San Francisco and the director of Melanoma Clinical Research at the UCSF Helen Diller Family Comprehensive Cancer Center

Adil Daud, MD

Combining the PD-1 inhibitor pembrolizumab (Keytruda) with intratumoral plasmid interkeukin-12 (IL-12; tavokinogene telseplasmid; Tavo) electroporation elicited clinical responses in patients with immunologically quiescent advanced melanoma, according to results of a single-arm, phase 2 study (NCT02493361) published in Clinical Cancer Research.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication